+38.6%
LRCX vs MRNA
+147.4%
-108.9%
-41.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.6% | +0.7% | -6.4% | -5.6% |
| 7D | +1.8% | -8.2% | +10.1% | +1.7% |
| 30D | -4.3% | +125.6% | -129.9% | -1.9% |
| 3M | -7.3% | +197.1% | -204.4% | -19.8% |
| 6M | +38.6% | +148.5% | -109.9% | +29.9% |
| All | +38.6% | +147.4% | -108.9% | +29.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling